IRCCS - AOU di Bologna

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Chronic lymphocytic leukaemia2 trials
• Mantle cell lymphoma2 trials
• Obesity2 trials
• Type 2 diabetes2 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Heart failure1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Peripheral artery disease1 trial
• and 2 more

Phase

• Phase 34 trials
• Phase 12 trials
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Completed2 trials
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company6 trials
• Nurix Therapeutics, Inc.1 trial

Running trials

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

  NCT02411448· Phase 3· Eli Lilly and Company· Source

Closed trials

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

  NCT05462756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  NCT05131022· Phase 1· Nurix Therapeutics, Inc.· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Eli Lilly and Company· Source